Portfolio Companies News
April 24, 2018Targovax ASA: Invitation to first q...
Oslo, Norway, 24 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2018 results on Thursday, 3 May 2018. A presentation by Targovax's management to investors, analysts and the press ... read more
April 23, 2018MIPS receives a positive decision i...
3:40 pm / April 23, 2018 MIPS AB (”MIPS”) has previously filed an opposition at the European Patent Office against European Patent 2,550,886 (the “Patent”), granted to Bauer Hockey Corp. (“Bauer”). The Patent relates to a sports helmet with rotational impact protection, based on a ... read more
April 20, 2018Nexstim Plc to present at BioTrinit...
Press release, Helsinki, 20 April 2018, at 12 noon Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic application, announces that... read more
April 19, 2018MIPS and POC Sweden have reached a ...
4:00 pm / April 19, 2018 On November 15, 2017 MIPS AB (”MIPS”) disclosed that the company had been granted a preliminary injunction in Germany in order to prevent an infringement by POC Sweden AB (”POC”) of one of MIPS’ patents. Following POC’s opposition the preliminary injun... read more
April 16, 2018Aprea Therapeutics Presents Results...
- ORR (by IWG) of 100% in all evaluable patients: 6 CR (75%) and 2 mCR (25%) - All CR patients achieved complete cytogenetic response - No responding patients have experienced relapse - No treatment-related serious adverse events or dose-limiting toxicities to date BOSTON, MA. and STOCKHOLM, S... read more
February 07, 2018Q4 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 110 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.